



Press Release

Piramal Enterprises announces Q4 and full year FY2013 result; the Board of Directors has recommended a dividend of ₹ 17.5 per equity share (875%) for FY2013

Total operating income for FY13 up by 50.7% to ₹ 3,544.3 crores,

Mumbai, 3rd May 2013: Piramal Enterprises Limited (formerly Piramal Healthcare Limited) ('PEL', NSE: PEL, BSE: 500302) today announced results for FY2013 and for Q4 FY2013.

For the year ended 31st March 2013, the Board of Directors has recommended a dividend of ₹ 17.5 per share (i.e. 875%) of face value of ₹ 2. Total dividend outgo (including dividend distribution tax) will be ₹ 353 crores.

For the quarter ended Q4 FY2013, the Total operating income grew by 36.4% to ₹ 938.6 crores against ₹ 688.1 crores in Q4 FY2012. Operating Profit (OPBITDA) for the quarter was ₹ 95.7 crores in Q4 FY2013 as compared with ₹ 78.2 crores during the same period last year. Net Income for the quarter was a net loss of ₹ 200.4 crores as compared with net loss of ₹ 38.7 crores during Q4 FY2012.

For the full year FY2013, the total operating income was up by 50.7% to ₹ 3,544.3 crores as compared with FY 2012. The Operating Profit for the financial year ended was at ₹ 455.9 crores against ₹ 192.5 crores in the previous financial year. FY 2013 results also include the financial results of Decision Resources Group ('DRG') and Piramal Imaging operations in Germany. For FY 2013, PEL reported a Net loss of ₹ 227.3 crores as compared with net profit of ₹ 111.5 crores in FY2012. PEL spent ₹ 286.7 crores on R&D this year as against ₹ 233.1 crores in FY 2012. Interest cost was higher at ₹ 575.0 crores for FY2013 as compared with ₹ 215.5 crores during FY 2012. The higher interest cost was a result debt raised by PEL to fund acquisitions of Vodafone shares, DRG and to fund financial services business.

For further information on the financials, please visit our website: www.piramalenterprises.com

Note to the Editors:

About the Piramal Group

The Piramal Group, led by Ajay G. Piramal is one of India's foremost business conglomerates. Driven by the core values of Knowledge Action Care, the Piramal Group has interests in a myriad of industries that encompass healthcare, drug discovery & research, diagnostics, glass, real estate and financial services. The Piramal Group steadfastly pursues inclusive growth while adhering to ethical and value driven practices. The Group's turnover exceeded \$ 1 billion in FY2013.

About Piramal Enterprises Ltd.

Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of over \$ 650 million in FY2013. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectible anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund – Indiareit and a NBFC that is focused on lending to real estate and education sector. PEL's information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry.

For investor enquiries, please contact:

Jatin Lal / Aishwarya Sitharam,
Investor Relations Team,
Piramal Enterprises Limited
Tel: +91 (0) 22 3046 6582 / 6446
investor.relations@piramal.com

For media enquiries, please contact:

PIRAMAL ENTERPRISES LIMITED Akansha Pradhan / Riddhi Goradia Corporate Communications, Piramal Group Contact: +91 22 3351 4082 / 4083 akansha.pradhan@piramal.com riddhi.goradia@piramal.com	PUBLIC RELATIONS AGENCY Janhavi Bellare / Rakesh Reddy Hanmer MSL Tel: +91-22-6633 5969 Mobile: +91 9322854508 / +91 9321735515 Janhavi.bellare@hanmermsl.com rakesh.reddy@hanmermsl.com
--	--